Merrimack Pharmaceuticals, Inc. (MACK)

Trade MACK now with
3/12/2018 6:30:20 AM Merrimack Pharma Q4 Loss Attributable To Cont Opns $11.8 Mln Or $0.89/Shr Vs Loss $40.1 Mln Or $2.93/Shr Last Year
3/12/2018 6:29:04 AM Merrimack Pharma Expands Enrollment In Ongoing Randomized Phase 2 SHERLOC Study Of MM-121 In Non-small Cell Lung Cancer
2/26/2018 6:57:02 AM Merrimack Doses First Patient In Randomized Phase 2 Clinical Study Of MM-121
11/30/2017 6:51:00 AM Merrimack Appoints George Demetri To Board Of Directors
11/8/2017 6:43:27 AM Merrimack Pharma Posts Q3 Net Loss Of $5.4 Mln Or $0.40/share
10/30/2017 7:00:56 AM Merrimack: FDA Granted Orphan Drug Designation To MM-121 For Treatment Of Heregulin Positive Non-small Cell Lung Cancer
8/9/2017 6:59:02 AM Merrimack Pharma Q2 Loss From Cont. Ops. Narrows To $28.9 Mln Or $0.22/shr From $51.4 Mln Or $0.41/shr Last Year
6/29/2017 6:01:22 AM Hercules Capital Announces Addl Portfolio Company Liquidity Events; Portfolio Companies Currently In IPO Registration
6/19/2017 6:56:35 AM Merrimack Completes Enrollment In Phase 2 CARRIE Study Of MM-141; Data Expected In First Half Of 2018
6/8/2017 6:57:01 AM Merrimack Appoints Sergio Santillana As Chief Medical Officer And Ellen Forest As Head Of Human Resources
5/10/2017 6:47:13 AM Merrimack Pharma Posts Q1 Net Loss Of $30.15 Mln Or $0.23/share
4/17/2017 7:03:06 AM Merrimack Appoints Daryl Drummond As Head Of Research
4/17/2017 6:02:42 AM Hercules Capital Reports Unscheduled Principal Repayments “early Pay-offs” Of $100.3 Mln For Q1
3/23/2017 7:03:49 AM Merrimack Enrolls First Patient In Phase 1 Study Of MM-310 In Solid Tumors
3/1/2017 7:14:06 AM Merrimack 2016 Net Loss Attributable $151.7 Mln Or $1.21 Per Share
2/23/2017 4:14:29 PM Hercules Q4 Distributable Net Operating Income $34.5 Mln Or $0.45 Per Share
1/18/2017 7:32:25 AM Merrimack Names Richard Peters As President And CEO